A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations

Protocol No
SWOG-LUNGMAP-S1900C
Principal Investigator
Smitha Menon
Phase
II
Summary
This study is being done to answer the following question: Can we increase the ability of your immune system to fight lung cancer and lower the chance of your lung cancer growing or spreading by using a combination of talazoparib and avelumab? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your non-squamous non-small cell lung cancer. The usual approach is defined as care most people get for their non-squamous non-small cell lung cancer.
Description
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small
Participating Institutions
Froedtert West Bend Hospital
Froedtert Hospital
Froedtert Menomonee Falls Hospital
Status
OPEN TO ACCRUAL
Share This: